Related Experiment Video
Updated: Apr 27, 2026
Analysis of Yersinia enterocolitica Effector Translocation into Host Cells Using Beta-lactamase Effector Fusions
Published on: October 13, 2015
Analysis of Y-P30/Dermcidin expression and properties of the Y-P30 peptide
Marina Mikhaylova, Anne Schumacher, Corinna Borutzki
1RG Neuroplasticity, Leibniz-Institute for Neurobiology, Magdeburg 39118, Germany. ana.zenclussen@med.ovgu.de.
Background:
The survival promoting peptide Y-P30 has a variety of neuritogenic and neuroprotective effects in vitro and in vivo. In previous work we reported the expression of Y-P30/dermcidin in maternal peripheral blood mononuclear cells (PBMCs) and the transport of the protein to the fetal brain. In this study we analyzed hormonal regulation of Y-P30 in human immune cells and expression of Y-P30 in the placenta. We further studied the stability and secretion of the Y-P30 peptide.
Results:
We found indications that Y-P30 might be produced in human placenta. The Y-P30 mRNA was rarely found in isolated human PBMCs and alpha-feto-protein, human chorionic gonadotropin as well as estradiol combined with progesterone could not induce Y-P30 expression. Y-P30 was found to be extraordinarily stable; therefore, contamination with the peptide and the Y-P30/Dermcidin precursor mRNA is a serious concern in experiments looking at the expression of Y-P30/Dermcidin. In cultured cell lines and primary neurons we found that Y-P30 could be released, but neuronal uptake of Y-P30 was not observed.
Conclusions:
Our data suggest that a source of Y-P30 apart from eccrine glands might be the placenta. The peptide can be secreted together with the signaling peptide and it might reach the fetal brain where it can exert its neuritogenic functions by binding to neuronal membranes.
Insights
The placenta may produce the survival peptide Y-P30, which has neuroprotective effects. This peptide
Area of Science:
- Neuroscience
- Immunology
- Endocrinology
Background:
- The survival-promoting peptide Y-P30 exhibits neuritogenic and neuroprotective properties.
- Previous studies indicated Y-P30/dermcidin expression in maternal peripheral blood mononuclear cells (PBMCs) and transport to the fetal brain.
Purpose of the Study:
- To investigate the hormonal regulation of Y-P30 in human immune cells.
- To examine Y-P30 expression in the placenta.
- To assess the stability and secretion of the Y-P30 peptide.
Main Methods:
- Analysis of Y-P30 mRNA in isolated human PBMCs.
- Hormonal induction studies using alpha-fetoprotein, human chorionic gonadotropin, estradiol, and progesterone.
- Assessment of Y-P30 stability and release from cultured cell lines and primary neurons.
Main Results:
- Y-P30 mRNA was rarely detected in isolated human PBMCs.
- Hormonal treatments did not induce Y-P30 expression in PBMCs.
- Y-P30 demonstrated remarkable stability, raising concerns about experimental contamination.
- Y-P30 was released from cultured cells, but neuronal uptake was not observed.
Conclusions:
- The placenta is a potential source of Y-P30, distinct from eccrine glands.
- Y-P30 can be secreted and may reach the fetal brain.
- The peptide may exert neuritogenic functions by binding to neuronal membranes in the fetal brain.
